Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Phase 3

Active, not recruiting

Conditions: Invasive Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pertuzumab
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Surgery
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Atezolizumab

First Posted Date: 2018-07-23

Last Posted Date: 2024-03-06

Lead Sponsor: Fondazione Michelangelo

Target Recruit Count: 650

Registration Number: NCT03595592

Locations: 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸
Hospital Virgen de la Nieves, Granada, Spain
🇮🇹
Ospedale Santa Maria della Misericordia, Udine, Italy

and more 62 locations

Cardiac Safe Transplants for Systemic Sclerosis

Phase 2

Terminated

Conditions: Systemic Sclerosis
Scleroderma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: G-CSF
Biological: IVIg
Biological: Autologous Stem Cells

First Posted Date: 2018-07-20

Last Posted Date: 2020-08-12

Lead Sponsor: Northwestern University

Target Recruit Count: 9

Registration Number: NCT03593902

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Conditions: Acute Lymphoblastic Leukemia
Immune System Diseases
Immunoproliferative Disorders

First Posted Date: 2018-07-20

Last Posted Date: 2021-12-03

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Registration Number: NCT03594162

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Aldoxorubicin HCl
Biological: ALT-803
Biological: ETBX-011
Biological: ETBX-021
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6207
Biological: GI-6301
Biological: haNK for infusion
Biological: bevacizumab
Drug: Capecitabine
Drug: Cyclophosphamide
Drug: Fluorouracil
Drug: Leucovorin
Drug: nab-Paclitaxel
Drug: Oxaliplatin
Biological: Avelumab
Procedure: SBRT

First Posted Date: 2018-07-16

Last Posted Date: 2024-08-27

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 3

Registration Number: NCT03586869

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Phase 1

Completed

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Nivolumab
Drug: Etoposide
Drug: Prednisolone
Drug: Oncovin
Drug: Cyclophosphamide
Drug: Hydroxydaunorubicin

First Posted Date: 2018-07-16

Last Posted Date: 2024-10-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 18

Registration Number: NCT03586999

Locations: 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors

Phase 1

Active, not recruiting

Conditions: Childhood Solid Tumor

Interventions: Drug: Vinblastine
Drug: Capecitabine
Drug: Cyclophosphamide
Drug: Nivolumab

First Posted Date: 2018-07-13

Last Posted Date: 2024-05-06

Lead Sponsor: Centre Oscar Lambret

Target Recruit Count: 63

Registration Number: NCT03585465

Locations: 🇧🇪
University Hospital Ghent, Gent, Belgium
🇧🇪
University Hospital Leuven, Leuven, Belgium
🇫🇷
Centre Oscar Lambret, Lille, France

and more 8 locations

CD19-Specific T Cells Post AlloSCT

Phase 1

Terminated

Conditions: B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Ph-Like Acute Lymphoblastic Leukemia
Refractory Small Lymphocytic Lymphoma
Recurrent Non-Hodgkin Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-07-09

Last Posted Date: 2021-06-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03579888

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Liver Transplantation With Tregs at MGH

Phase 1

Active, not recruiting

Conditions: Liver Transplant

Interventions: Biological: arTreg-CSB
Procedure: leukapheresis
Drug: cyclophosphamide
Drug: mesna
Drug: everolimus

First Posted Date: 2018-07-05

Last Posted Date: 2023-12-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 9

Registration Number: NCT03577431

Locations: 🇺🇸
Massachusetts General Hospital: Transplantation, Boston, Massachusetts, United States

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Nab-paclitaxel
Drug: Cisplatin
Drug: 5Fluorouracil
Drug: Docetaxel
Drug: carboplatin
Drug: Cyclophosphamide
Biological: ETBX-011
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6301
Drug: Aldoxorubicin
Drug: Avelumab
Drug: ALT-803
Biological: haNK

First Posted Date: 2018-07-02

Last Posted Date: 2022-04-05

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03574649

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Phase 1

Withdrawn

Conditions: Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Cyclophosphamide
Biological: IRX-2
Biological: Nivolumab
Procedure: Surgery

First Posted Date: 2018-07-02

Last Posted Date: 2019-08-28

Lead Sponsor: Emory University

Registration Number: NCT03575234

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy